Pridopidine | ACR16 | CAS#346688-38-8 | dopamine stabilizer

MedKoo Cat#: 319772 | Name: Pridopidine

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pridopidine, also known as ACR16, is a dopamine stabilizer, which improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model. Huntington disease (HD) is a neurodegenerative disorder for which new treatments are urgently needed. Pridopidine is a new dopaminergic stabilizer, recently developed for the treatment of motor symptoms associated with HD.

Chemical Structure

Pridopidine

CAS#346688-38-8

Theoretical Analysis

MedKoo Cat#: 319772

Name: Pridopidine

CAS#: 346688-38-8

Chemical Formula: C14H20FNO2S

Exact Mass: 285.1199

Molecular Weight: 285.38

Elemental Analysis: C, 58.92; H, 7.06; F, 6.66; N, 4.91; O, 11.21; S, 11.23

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 500.00	2 Weeks
50mg	USD 1,050.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ACR16; ACR-16; ACR 16; ACR16 compound; FR310826; FR-310826; FR 310826; Pridopidine

IUPAC/Chemical Name

4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin

InChi Key

UKUPJASJNQDHPH-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H20FNO2S/c1-3-16-9-7-11(8-10-16)12-5-4-6-13(14(12)15)19(2,17)18/h4-6,11H,3,7-10H2,1-2H3

SMILES Code

O=S(C1=C(F)C(C2CCN(CC)CC2)=CC=C1)(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 285.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Neel DV, Baselga-Garriga C, Benson M, Keegan M, Chase M, D'Agostino D, Drake K, Hagar JL, Hasenoehrl MG, Kulesa-Kelley J, Leite A, Mohapatra S, Portaro SM, Pothier LM, Rosenthal J, Sherman AV, Yu H, McCaffrey A, Ho D, Luppino S, Bedlack R, Heitzman D, Ajroud-Driss S, Katz J, Felice K, Whitaker C, Ladha S, Alameda G, Locatelli E, Qureshi IA, Hotchkin MT, Hayden MR, Cudkowicz ME, Babu S, Berry JD, Paganoni S. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis. Muscle Nerve. 2024 Aug;70(2):232-239. doi: 10.1002/mus.28169. Epub 2024 Jun 6. PMID: 38842106. 2: Ludwig FA, Laurini E, Schmidt J, Pricl S, Deuther-Conrad W, Wünsch B. [18F]Fluspidine-A PET Tracer for Imaging of σ1 Receptors in the Central Nervous System. Pharmaceuticals (Basel). 2024 Jan 28;17(2):166. doi: 10.3390/ph17020166. PMID: 38399380; PMCID: PMC10892410. 3: Oudejans E, Witkamp D, Hu-A-Ng GV, Hoogterp L, van Rooijen-van Leeuwen G, Kruijff I, Schonewille P, Lalaoui El Mouttalibi Z, Bartelink I, van der Knaap MS, Abbink TE. Pridopidine subtly ameliorates motor skills in a mouse model for vanishing white matter. Life Sci Alliance. 2024 Jan 3;7(3):e202302199. doi: 10.26508/lsa.202302199. PMID: 38171595; PMCID: PMC10765115. 4: Van de Roovaart HJ, Nguyen N, Veenstra TD. Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis. Pharmaceuticals (Basel). 2023 Oct 24;16(11):1513. doi: 10.3390/ph16111513. PMID: 38004378; PMCID: PMC10674993. 5: Ruiz-Cantero MC, Huerta MÁ, Tejada MÁ, Santos-Caballero M, Fernández-Segura E, Cañizares FJ, Entrena JM, Baeyens JM, Cobos EJ. Sigma-1 receptor agonism exacerbates immune-driven nociception: Role of TRPV1 + nociceptors. Biomed Pharmacother. 2023 Nov;167:115534. doi: 10.1016/j.biopha.2023.115534. Epub 2023 Sep 18. PMID: 37729726. 6: Malar DS, Thitilertdecha P, Ruckvongacheep KS, Brimson S, Tencomnao T, Brimson JM. Targeting Sigma Receptors for the Treatment of Neurodegenerative and Neurodevelopmental Disorders. CNS Drugs. 2023 May;37(5):399-440. doi: 10.1007/s40263-023-01007-6. Epub 2023 May 11. PMID: 37166702; PMCID: PMC10173947. 7: Pascarella G, Antonelli L, Narzi D, Battista T, Fiorillo A, Colotti G, Guidoni L, Morea V, Ilari A. Investigation of the Entry Pathway and Molecular Nature of σ1 Receptor Ligands. Int J Mol Sci. 2023 Mar 28;24(7):6367. doi: 10.3390/ijms24076367. PMID: 37047338; PMCID: PMC10094450. 8: Darpo B, Geva M, Ferber G, Goldberg YP, Cruz-Herranz A, Mehra M, Kovacs R, Hayden MR. Pridopidine Does Not Significantly Prolong the QTc Interval at the Clinically Relevant Therapeutic Dose. Neurol Ther. 2023 Apr;12(2):597-617. doi: 10.1007/s40120-023-00449-w. Epub 2023 Feb 22. PMID: 36811812; PMCID: PMC10043059. 9: Jiang J, Wang Y, Deng M. New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022. Front Pharmacol. 2022 Nov 28;13:1054006. doi: 10.3389/fphar.2022.1054006. PMID: 36518658; PMCID: PMC9742490. 10: Bezprozvanny I. Alzheimer's disease - Where do we go from here? Biochem Biophys Res Commun. 2022 Dec 10;633:72-76. doi: 10.1016/j.bbrc.2022.08.075. PMID: 36344168. 11: Lenoir S, Lahaye RA, Vitet H, Scaramuzzino C, Virlogeux A, Capellano L, Genoux A, Gershoni-Emek N, Geva M, Hayden MR, Saudou F. Pridopidine rescues BDNF/TrkB trafficking dynamics and synapse homeostasis in a Huntington disease brain-on-a-chip model. Neurobiol Dis. 2022 Oct 15;173:105857. doi: 10.1016/j.nbd.2022.105857. Epub 2022 Sep 6. PMID: 36075537. 12: Estévez-Silva HM, Cuesto G, Romero N, Brito-Armas JM, Acevedo-Arozena A, Acebes Á, Marcellino DJ. Pridopidine Promotes Synaptogenesis and Reduces Spatial Memory Deficits in the Alzheimer's Disease APP/PS1 Mouse Model. Neurotherapeutics. 2022 Sep;19(5):1566-1587. doi: 10.1007/s13311-022-01280-1. Epub 2022 Aug 2. PMID: 35917088; PMCID: PMC9606189. 13: Wang SM, Wu HE, Yasui Y, Geva M, Hayden M, Maurice T, Cozzolino M, Su TP. Nucleoporin POM121 signals TFEB-mediated autophagy via activation of SIGMAR1/sigma-1 receptor chaperone by pridopidine. Autophagy. 2023 Jan;19(1):126-151. doi: 10.1080/15548627.2022.2063003. Epub 2022 May 4. PMID: 35507432; PMCID: PMC9809944. 14: Bogár F, Fülöp L, Penke B. Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands. Biomolecules. 2022 Feb 25;12(3):363. doi: 10.3390/biom12030363. PMID: 35327555; PMCID: PMC8945408. 15: Cenci MA, Skovgård K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology. 2022 Jun 1;210:109027. doi: 10.1016/j.neuropharm.2022.109027. Epub 2022 Mar 12. PMID: 35292330. 16: Klopstock T, Hall D, Frucht S, Flamand-Roze E. Editorial: Advances in Therapeutics for Hyperkinetic Movement Disorders. Front Neurol. 2022 Feb 24;13:853084. doi: 10.3389/fneur.2022.853084. PMID: 35280292; PMCID: PMC8907508. 17: Estévez-Silva HM, Mediavilla T, Giacobbo BL, Liu X, Sultan FR, Marcellino DJ. Pridopidine modifies disease phenotype in a SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2022 Mar;55(5):1356-1372. doi: 10.1111/ejn.15608. Epub 2022 Feb 12. PMID: 35080077; PMCID: PMC9305776. 18: Asla MM, Nawar AA, Abdelsalam A, Elsayed E, Rizk MA, Hussein MA, Kamel WA. The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis. Mov Disord Clin Pract. 2021 Oct 29;9(1):20-30. doi: 10.1002/mdc3.13357. PMID: 35005061; PMCID: PMC8721839. 19: Geva M, Gershoni-Emek N, Naia L, Ly P, Mota S, Rego AC, Hayden MR, Levin LA. Neuroprotection of retinal ganglion cells by the sigma-1 receptor agonist pridopidine in models of experimental glaucoma. Sci Rep. 2021 Nov 9;11(1):21975. doi: 10.1038/s41598-021-01077-w. PMID: 34753986; PMCID: PMC8578336. 20: Chen S, Liang T, Xue T, Xue S, Xue Q. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front Neurol. 2021 May 13;12:658123. doi: 10.3389/fneur.2021.658123. PMID: 34054700; PMCID: PMC8159155.